At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 254 enrolled
Drug / intervention
Teneligliptin 20mg +1 moredrug
Likely dose
Teneligliptin 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating Teneligliptin 20mg and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 254 participants across 1 site.
Detailed Summary
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedSep 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedSep 27, 2016
Enrollment StartSep 1, 2016
Primary CompletionAug 14, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.8 years ago
Interventions
Teneligliptin 20mgdrug
Placebodrug